Elekta (EKTA) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
21 Nov, 2025Strategic focus and market positioning
Emphasis on profitability, margin expansion, and sustainable growth, with a shift to only accepting profitable orders and canceling non-accretive backlog items.
Strong market positions in Europe and China, with tailored strategies for mature and emerging markets to maximize value and growth.
Leadership in high-margin segments such as brachytherapy, neuro, and software, with a dual-engine growth model leveraging both new installations and upselling to the installed base.
Adaptive radiotherapy and software innovation are central to product differentiation and customer value, especially with Elekta ONE and Evo platforms.
Strategic partnerships and selective acquisitions support market access and product portfolio expansion, particularly in China and software.
Leadership and strategic direction
Jakob Just-Bomholt appointed as new President and CEO, effective September 1, bringing international experience in growth and profitability from previous executive roles.
Transition from ACCESS 2025 strategy to a focus on margin-accretive growth, efficiency, and operational excellence.
Emphasis on upselling to the expanded installed base and targeting selected profitable markets with incremental innovation.
Financial performance and guidance
Achieved record Q4 gross margin, attributed to volume growth, price increases, product mix, and productivity improvements.
Mid-term targets reaffirmed: EBIT margin north of 14% and gross margin above 40%, with continued focus on price increases and high-margin product acceleration.
Backlog reviewed and non-accretive orders canceled, resulting in a SEK 37 billion executable backlog, 82% of which is planned for delivery within three years.
Software revenue grew 7% year-over-year, with orders up over 20%, and SaaS now representing a significant and growing share, especially in the U.S.
Impairment of SEK 1,064M due to discontinued R&D projects, mainly in software, with a shift to external cloud platforms.
Latest events from Elekta
- Adjusted gross margin rose to 38.3% as restructuring costs and FX reduced net income.EKTA
Q3 20265 Mar 2026 - SEK 500m+ savings, job cuts, and innovation drive target growth in China and US.EKTA
Strategy update2 Feb 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Record cash flow and European growth offset US and China weakness; margin guidance lowered.EKTA
Q3 24/2527 Dec 2025 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025